- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
III
II
Principal Investigator(s)
Quarraisha Abdool Karim, PhD
Objective
To assess the effectiveness of an implementation model which integrates tenofovir gel provision into existing family planning services.
Prevention Option(s)
Microbicides
Study Design
Controlled
Placebo
Arms and Assigned Interventions
Description
1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of QI methodology to promote reliable service delivery
Mode of Delivery
Gel
Products
1% tenofovir gel
ARMs
Experimental
Description
monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
Mode of Delivery
Gel
ARMs
Placebo Comparator
Official Code
Trial Sponsors
Centre for the AIDS Programme of Research in South Africa, CONRAD, Gilead Sciences, FHI 360, Institute for Health Care Improvement
October 2012
December 2015
Enrollment
700
18
Years
Population
Women
Sites
CAPRISA eThekwini Clinical Research Site
Durban, KwaZulu-Natal
South Africa
CAPRISA Vulindlela Clinical Research Site
Pietermaritzburg, KwaZulu-Natal
South Africa